St. Jude discloses warning letter; TearScience closes on $44.5M round of financing;

> St. Jude Medical received a warning letter on April 23 from U.S. regulators citing the marketing of its Epicor LP Cardiac Ablation System and Epicor UltraCinch LP ablation device, the company said Tuesday in a regulatory filing. Story

> TearScience has closed on a $44.5 million third round of venture capital financing aimed at ramping up the company's operations as it brings its new dry eye medical device to market. Story

> Wright Medical Group Inc., an orthopaedic medical device maker, posted quarterly results above market estimates, helped by strong hip and extremity product sales, and backed its full-year outlook. Report

> Patients who have undergone coronary stenting and who subsequently require noncardiac surgery are less likely to die or have an ischemic event if the surgery is performed at least 6 weeks after the stent is placed, according to a new study published online May 4 in Circulation: Cardiovascular Interventions. In addition, the risks after noncardiac surgery are similar regardless of whether the patient receives a bare-metal stent or a drug-eluting stent. Item

> Boston Scientific Corp. enrolled the first patient in its Evidence clinical trial comparing spinal cord stimulation with second operations for patients whose first back surgeries failed. Report

> Bruce Peacock, a venture partner with SV Life Sciences, has some advice for budding biotech entrepreneurs: Take a page from the medical-device playbook. Report

And Finally... The Cleveland Clinic has admitted that its former staff physician and inventor, Dr. Jay Yadav, did not run afoul of the health system's conflict of interest policy as it had claimed in 2006 while declining to renew Yadav's employment contract. Report

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.